KR20260021814A - 생물학적 활성 복합체의 제조방법 - Google Patents

생물학적 활성 복합체의 제조방법

Info

Publication number
KR20260021814A
KR20260021814A KR1020267002686A KR20267002686A KR20260021814A KR 20260021814 A KR20260021814 A KR 20260021814A KR 1020267002686 A KR1020267002686 A KR 1020267002686A KR 20267002686 A KR20267002686 A KR 20267002686A KR 20260021814 A KR20260021814 A KR 20260021814A
Authority
KR
South Korea
Prior art keywords
biologically active
active complex
peptide
complex
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267002686A
Other languages
English (en)
Korean (ko)
Inventor
애프탑 나딤
카나리나 스반보르그
친 싱 호
Original Assignee
햄릿 파르마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 햄릿 파르마 에이비 filed Critical 햄릿 파르마 에이비
Publication of KR20260021814A publication Critical patent/KR20260021814A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Inorganic Chemistry (AREA)
KR1020267002686A 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법 Pending KR20260021814A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1707715.7 2017-05-14
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes
KR1020197037015A KR20200015557A (ko) 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법
PCT/EP2018/062396 WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037015A Division KR20200015557A (ko) 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법

Publications (1)

Publication Number Publication Date
KR20260021814A true KR20260021814A (ko) 2026-02-13

Family

ID=59201543

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267002686A Pending KR20260021814A (ko) 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법
KR1020197037015A Ceased KR20200015557A (ko) 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197037015A Ceased KR20200015557A (ko) 2017-05-14 2018-05-14 생물학적 활성 복합체의 제조방법

Country Status (13)

Country Link
US (3) US20200140481A1 (https=)
EP (2) EP3618848B1 (https=)
JP (2) JP7672122B2 (https=)
KR (2) KR20260021814A (https=)
CN (2) CN110650746B (https=)
AU (1) AU2018269304B2 (https=)
CA (1) CA3063285A1 (https=)
DK (2) DK3618848T3 (https=)
ES (2) ES2973290T3 (https=)
FI (1) FI3811967T3 (https=)
GB (1) GB201707715D0 (https=)
PL (2) PL3811967T3 (https=)
WO (1) WO2018210759A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
US20220323391A1 (en) * 2019-08-20 2022-10-13 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
AU2023357946A1 (en) 2022-10-03 2025-04-24 Linnane Pharma Ab A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
DK2385954T3 (da) 2009-01-09 2013-06-17 Hamlet Pharma Ab Kompleks og fremstillingsproces
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
DK2643010T3 (en) 2010-11-24 2017-02-27 Hamlet Pharma Ab BIOLOGICAL ACTIVE COMPLEX AND ITS PREPARATION
EP3295953B1 (en) * 2012-08-09 2020-10-21 HAMLET Pharma AB Milk protein - fatty acid complex
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Also Published As

Publication number Publication date
JP2020519673A (ja) 2020-07-02
CN110650746A (zh) 2020-01-03
JP2023075290A (ja) 2023-05-30
AU2018269304B2 (en) 2025-02-27
EP3811967A1 (en) 2021-04-28
CN119700935A (zh) 2025-03-28
DK3618848T3 (da) 2021-03-01
EP3618848A1 (en) 2020-03-11
US20200140481A1 (en) 2020-05-07
WO2018210759A1 (en) 2018-11-22
ES2973290T3 (es) 2024-06-19
GB201707715D0 (en) 2017-06-28
EP3618848B1 (en) 2020-11-25
CN110650746B (zh) 2024-12-31
US12331073B2 (en) 2025-06-17
PL3811967T3 (pl) 2024-03-18
US20260085088A1 (en) 2026-03-26
US20210130394A1 (en) 2021-05-06
JP7705160B2 (ja) 2025-07-09
DK3811967T5 (da) 2024-08-19
DK3811967T3 (da) 2024-01-08
PL3618848T3 (pl) 2021-06-14
JP7672122B2 (ja) 2025-05-07
FI3811967T3 (fi) 2023-12-28
ES2861252T3 (es) 2021-10-06
EP3811967B1 (en) 2023-12-20
AU2018269304A1 (en) 2019-11-21
CA3063285A1 (en) 2018-11-22
KR20200015557A (ko) 2020-02-12

Similar Documents

Publication Publication Date Title
JP7705160B2 (ja) 生物活性複合体の調製
Wang et al. Self-assembling peptide-based nanodrug delivery systems
JP5705118B2 (ja) 薬物送達のためのエトポシドおよびドキソルビシン複合体
JP2018521998A (ja) 癌細胞及び腫瘍関連マクロファージを同時に標的する融合ペプチドを有効成分として含む抗癌及び癌転移抑制用薬学的組成物
JP2023545152A (ja) アンフォールディングタンパク質を含む組成物の調製方法
TWI579299B (zh) 去整合蛋白變異體及其醫藥用途
KR102545825B1 (ko) 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
EP2729495B1 (fr) Peptide antagoniste de la liaison entre le cd47 et une proteine appartenant a la famille des thrombospondines
HK40050699A (en) Preparation of biologically active complexes
HK40050699B (en) Preparation of biologically active complexes
ES3040184T3 (en) Fusion protein preparation comprising il-2 and cd80 proteins
HK40025666B (en) Biologically active complexes and therapeutic uses thereof
HK40025666A (en) Biologically active complexes and therapeutic uses thereof
CN110981943A (zh) 多肽及其在制备药物中的用途和药物
CN109734779B (zh) 一种靶向Tie-1的多肽及其应用
JP2003522116A (ja) 細胞内信号伝達を攪乱させる合成ペプチド
JP2023540800A (ja) リフォールディングされたヒト血清アルブミン及びその抗腫瘍ための使用

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000